Predicting response to immune checkpoint blockade therapy among mismatch repair-deficient patients using mutational signatures
D. Gulhan, Vinay Viswanadham, Francesc Muyas…·Peter J. Park
The paper identifies mutational signatures SBS26 and SBS54 in MMRD tumors that correlate with immune checkpoint blockade response and survival, suggesting their use as prognostic biomarkers.